ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 9.31
-0.31 (-3.22%)
Jun 11, 2026, 3:04 PM CST
SHE:300254 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 860.23 | 868.17 | 842.33 | 792.42 | 824.84 | 924.94 |
Other Revenue | 2.62 | 2.62 | 4.28 | 6.89 | 4.15 | 5.43 |
| 862.85 | 870.79 | 846.61 | 799.31 | 829 | 930.37 | |
Revenue Growth (YoY) | 2.86% | 2.86% | 5.92% | -3.58% | -10.90% | 9.71% |
Cost of Revenue | 287.23 | 285.24 | 283.21 | 259.45 | 251.21 | 290.06 |
Gross Profit | 575.63 | 585.54 | 563.39 | 539.86 | 577.79 | 640.32 |
Selling, General & Admin | 412.05 | 416.12 | 428.41 | 453.44 | 534.1 | 603.92 |
Research & Development | 50.65 | 50.8 | 56.53 | 49.97 | 54.52 | 57.12 |
Other Operating Expenses | 4.37 | 4.49 | -0.37 | 4.86 | 12.09 | 12.77 |
Operating Expenses | 471.72 | 476.48 | 490.35 | 507.84 | 601.43 | 668.48 |
Operating Income | 103.9 | 109.06 | 73.04 | 32.02 | -23.64 | -28.16 |
Interest Expense | -21.02 | -21.63 | -16.98 | -33.16 | -46.06 | -49.17 |
Interest & Investment Income | 5.02 | 4.22 | 5.86 | 24.63 | 2.55 | 15.74 |
Earnings From Equity Investments | - | - | - | - | -3.43 | - |
Currency Exchange Gain (Loss) | 0 | 0 | - | 0.01 | 0.62 | 0 |
Other Non Operating Income (Expenses) | 18.93 | 16.11 | 19.49 | 18.51 | -2.08 | -0.2 |
EBT Excluding Unusual Items | 106.83 | 107.76 | 81.42 | 42 | -72.05 | -61.8 |
Impairment of Goodwill | - | - | -4.26 | -4.1 | -19.58 | -19.6 |
Gain (Loss) on Sale of Investments | -18.93 | -18.93 | - | - | - | - |
Gain (Loss) on Sale of Assets | 1.06 | 8.94 | 7.51 | 18.8 | 0.69 | -0.37 |
Asset Writedown | -0.48 | -0.43 | -1.41 | -1.4 | -28.82 | -12.08 |
Other Unusual Items | -6.54 | -6.54 | -2.62 | -0.02 | 29.74 | 28.37 |
Pretax Income | 81.93 | 90.79 | 80.64 | 55.28 | -90.02 | -65.48 |
Income Tax Expense | 36.72 | 34.36 | 5.88 | 6.55 | 7.9 | 9.07 |
Earnings From Continuing Operations | 45.21 | 56.44 | 74.76 | 48.73 | -97.92 | -74.55 |
Minority Interest in Earnings | -27.41 | -31.59 | -32.57 | -23.53 | -20.6 | -16.89 |
Net Income | 17.8 | 24.85 | 42.19 | 25.2 | -118.52 | -91.44 |
Net Income to Common | 17.8 | 24.85 | 42.19 | 25.2 | -118.52 | -91.44 |
Net Income Growth | -48.09% | -41.10% | 67.45% | - | - | - |
Shares Outstanding (Basic) | 243 | 243 | 242 | 242 | 237 | 228 |
Shares Outstanding (Diluted) | 246 | 245 | 242 | 242 | 237 | 228 |
Shares Change (YoY) | 1.40% | 1.15% | 0.20% | 1.89% | 4.00% | 6.92% |
EPS (Basic) | 0.07 | 0.10 | 0.17 | 0.10 | -0.50 | -0.40 |
EPS (Diluted) | 0.07 | 0.10 | 0.17 | 0.10 | -0.50 | -0.40 |
EPS Growth | -48.81% | -41.77% | 67.11% | - | - | - |
Free Cash Flow | 79.63 | 62.45 | 19.44 | 3.9 | 48.09 | 59.99 |
Free Cash Flow Per Share | 0.32 | 0.26 | 0.08 | 0.02 | 0.20 | 0.26 |
Gross Margin | 66.71% | 67.24% | 66.55% | 67.54% | 69.70% | 68.82% |
Operating Margin | 12.04% | 12.52% | 8.63% | 4.00% | -2.85% | -3.03% |
Profit Margin | 2.06% | 2.85% | 4.98% | 3.15% | -14.30% | -9.83% |
Free Cash Flow Margin | 9.23% | 7.17% | 2.30% | 0.49% | 5.80% | 6.45% |
EBITDA | 154.78 | 160.06 | 124.55 | 84.61 | 34.66 | 35.55 |
EBITDA Margin | 17.94% | 18.38% | 14.71% | 10.59% | 4.18% | 3.82% |
D&A For EBITDA | 50.88 | 51 | 51.51 | 52.59 | 58.3 | 63.71 |
EBIT | 103.9 | 109.06 | 73.04 | 32.02 | -23.64 | -28.16 |
EBIT Margin | 12.04% | 12.52% | 8.63% | 4.00% | -2.85% | -3.03% |
Effective Tax Rate | 44.82% | 37.84% | 7.29% | 11.85% | - | - |
Revenue as Reported | 862.85 | 870.79 | 846.61 | 799.31 | 829 | 930.37 |
Advertising Expenses | - | 21.38 | 12.74 | 5.67 | 4.88 | 8.44 |